Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2006

View Archived Issues

Preclinical and clinical antithrombotic efficacy of rivaroxaban reported

Sequencing of human breast and colorectal cancers provides novel targets for drug design

AMD-3100 and G-CSF mobilize angiogenic cells, show wide clinical application

NovaDel Pharma adds oral spray drug development candidates to pipeline

Juvaris awarded SBIR grant for biodefense work

Anthera secures funding for novel secretory phospholipase programs

GSK reports on another successful quarter

Stem Cell Therapeutics options EPO programs in schizophrenia and MS

Phase IIa study of microplasmin in vitrectomy completes treatment

NuCana signs agreement with Cardiff ProTides to develop novel cancer agents

Bill & Melinda Gates Foundation supports efforts in hookworm and leishmaniasis

NV-1020 shows efficacy in liver metastases study

SQ-109 to begin clinical testing for tuberculosis

AstraZeneca and Schering to codevelop novel SERD for breast cancer

Phase II trial evaluates MGCD-0103 in relapsed or refractory B-cell lymphomas

Amgen presents novel TRPV1 antagonists with antinociceptive efficacy

SCV-07 shows oral bioavailability

Results for CTI-01 in cardiac surgery patients

Ginkgo biloba extract effective against postsurgical hypersensitivity

Efficacy of aliskiren/ramipril combination shown in hypertensive diabetic patients

Safety of ruboxistaurin in diabetic complications: results from 11 phase II and III trials

Antidiabetic efficacy of the DPP-IV inhibitor MP-513 shown in Zucker fatty rats

FDA approves first antifungal agent for prevention of IFIs caused by Aspergillus

Amgen reveals novel ACK1 inhibitors as anticancer candidates

Glivec approved in E.U. for additional cancer indications

Lyrica indications broadened in E.U. to include central neuropathic pain

Protherics seeks approval in U.S. for Voraxaze

Novel agents claimed for use in arthritis and other inflammatory disorders

Antipsoriatic agents prepared and tested at Relivia

New therapeutic agents for respiratory disorders revealed

Pfizer reports on promising anticancer development of new RTK inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...